Key Takeaways
- Clinical Bottom Line
- What Changed
- First-Line Treatment
- Salvage Therapy
Clinical Bottom Line
H. pylori treatment is now a resistance-management problem, not a rote triple-therapy prescription. For a busy GI practice, the practical shift is simple: avoid empiric clarithromycin regimens unless susceptibility is known, use optimized 14-day regimens, and document a test-of-cure for every treated patient.
| Practice Question | 2026 Practical Answer | What To Watch |
|---|---|---|
| What should be the empiric default? | Optimized bismuth quadruple therapy for 14 days is the safest default when susceptibility is unknown. | Pill burden is real. Provide written dosing instructions and side-effect counseling before the patient leaves. |
| When do PCAB regimens fit? | Vonoprazan-amoxicillin dual therapy or vonoprazan-based triple therapy can be useful when available and appropriate. | Clarithromycin-containing PCAB triple therapy still needs susceptibility or a strong reason to believe resistance is absent. |
| What after treatment failure? | Do not repeat a failed regimen. Review adherence, prior macrolide or quinolone exposure, penicillin allergy status, and local access to susceptibility testing. | Rifabutin-based therapy and optimized bismuth quadruple therapy are common salvage anchors, depending on prior exposure. |
| How do you close the loop? | Every treated patient needs test-of-cure using urea breath test, fecal antigen test, or biopsy-based testing. | Wait at least 4 weeks after antibiotics and bismuth, and hold PPI or PCAB for about 2 weeks when feasible. |
What Changed
The major change is the abandonment of reflexive PPI-clarithromycin-amoxicillin triple therapy in most North American empiric workflows. The 2024 ACG guideline emphasizes that clarithromycin and levofloxacin resistance have made older convenience regimens unreliable unless antimicrobial susceptibility is documented. In practice, that means the first prescription should be chosen with resistance in mind, and the chart should include a clear plan for eradication confirmation.
First-Line Treatment
Optimized bismuth quadruple therapy remains the most dependable empiric first-line regimen for many treatment-naive adults with confirmed active infection. The classic regimen combines a PPI, bismuth, tetracycline, and metronidazole for 14 days. It is effective because it avoids relying on clarithromycin susceptibility, but it is not easy for patients. The difference between a good prescription and a failed prescription is often the visit-level counseling: dosing schedule, dark stools, nausea, alcohol avoidance with metronidazole, and what to do if a dose is missed.
PCAB-based regimens have changed the conversation because vonoprazan produces potent acid suppression and simpler dosing in some packaged regimens. They are not a license to ignore resistance. Clarithromycin-containing regimens should still be reserved for patients with known susceptibility or a very low-risk resistance setting. Vonoprazan-amoxicillin dual therapy is attractive when pill burden and adherence are central issues, but patient selection and payer access often determine whether it is practical.
Salvage Therapy
After failure, the key step is to stop and reconstruct the antibiotic history. Ask about prior macrolides, fluoroquinolones, metronidazole exposure, adherence, side effects, and whether the patient completed the full course. If the patient failed clarithromycin therapy, repeating clarithromycin is usually a poor move. If they failed bismuth quadruple therapy because they could not tolerate or complete it, the next best regimen may be different from the next best regimen after true microbiologic failure.
When available, susceptibility testing is most useful after one or more failures, in patients with complex antibiotic exposure, or when there is a strong reason to preserve limited salvage options. Rifabutin-based therapy can be useful because resistance to amoxicillin and rifabutin is uncommon, but clinicians still need to review allergy history, interactions, adverse effects, and local availability.
Endoscopy and Test-of-Cure
The endoscopist’s role is not limited to taking biopsies. If H. pylori is found during EGD, the report should make it easy for the treating clinician to complete the loop: active infection documented, treatment recommended, and test-of-cure required. Serology is not a test-of-cure. Urea breath testing and stool antigen testing are the usual noninvasive options. Biopsy-based testing is reasonable when repeat endoscopy is being performed for another indication.
How To Apply This In Practice
- Use a default order set that no longer offers empiric clarithromycin triple therapy unless susceptibility is known.
- Give patients a printed or portal-based dosing schedule for bismuth quadruple therapy.
- Order the test-of-cure at the same time you prescribe treatment, with timing instructions attached.
- Document prior macrolide and quinolone exposure before salvage therapy.
- Consider formal penicillin allergy evaluation when the allergy history blocks the best regimen.
Selected Sources
- ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
- ACG H. pylori guideline highlights
Clinical update for gastroenterologists and endoscopists. Reviewed May 2026.
